&nbsp;

iccu-thumbnail-OH-inuit-postcard.jpg

Apr 2022

Document

iccu-thumbnail-OH-metis-postcard.jpg

Apr 2022

Regimen

ICE+RITU

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Intermediate Grade

Intent: Curative

Drugs Used:

riTUXimab (PDRP prior authorization),

mesna,

Quick Link(s):

Regimen Monograph

Jun 2022

Regimen

DABRTRAM

Cancer Type:

Central Nervous System

Intent: Palliative

Drugs Used:

daBRAFenib (Unfunded),

trametinib (Unfunded)

Quick Link(s):

Regimen Monograph

Jul 2022

Regimen

DOCE+TRAS

Cancer Type:

Head and Neck,

Salivary Gland

Intent: Palliative

Drugs Used:

trastuzumab (Unfunded),

DOCEtaxel

Quick Link(s):

Regimen Monograph

Jul 2022

Dépistage et prise en charge du virus de l'hépatite B chez les patients recevant un traitement systémique

Document

Indigenous_DrugCoverageSummary.pdf

Aug 2022

Document

Indigenous_DrugCoverageSummary_FR.pdf

Sep 2022

Statistical Reports

Data Sources [2022]

Regimen

DURV(MNT)

Cancer Type:

Gastrointestinal,

Hepatobiliary / Liver / Bile Duct

Intent: Palliative

Funding:

New Drug Funding Program

Durvalumab - Locally Advanced Unresectable or Metastatic Biliary Tract Cancer

New Drug Funding Program

Durvalumab in combination with Tremelimumab - Previously Untreated Unresectable or Metastatic Hepatocellular Carcinoma (HCC)

Drugs Used:

durvalumab

Quick Link(s):

Regimen Monograph

Apr 2024

Statistical Reports

Indice de qualité du système de prévention : Rapport spécial sur la prévention du cancer chez les personnes atteintes de troubles mentaux graves

Regimen

DURV+TREM

Cancer Type:

Gastrointestinal,

Hepatobiliary / Liver / Bile Duct

Intent: Palliative

Funding:

New Drug Funding Program

Durvalumab in combination with Tremelimumab - Previously Untreated Unresectable or Metastatic Hepatocellular Carcinoma (HCC)

New Drug Funding Program

Durvalumab in combination with Tremelimumab - Previously Untreated Unresectable or Metastatic Hepatocellular Carcinoma (HCC)

Drugs Used:

tremelimumab,

durvalumab